Kiniksa Pharmaceuticals Management
Management criteria checks 4/4
Kiniksa Pharmaceuticals' CEO is Sanj Patel, appointed in Jul 2015, has a tenure of 8.75 years. total yearly compensation is $5.30M, comprised of 16.3% salary and 83.7% bonuses, including company stock and options. directly owns 4.57% of the company’s shares, worth $57.06M. The average tenure of the management team and the board of directors is 3.3 years and 7.3 years respectively.
Key information
Sanj Patel
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 16.3% |
| CEO tenure | 8.8yrs |
| CEO ownership | 4.6% |
| Management average tenure | 3.3yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Nov 30Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
Nov 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
Compensation vs Market: Sanj's total compensation ($USD5.30M) is about average for companies of similar size in the US market ($USD5.61M).
Compensation vs Earnings: Sanj's compensation has been consistent with company performance over the past year.
CEO
Sanj Patel (54 yo)
8.8yrs
Tenure
US$5,297,067
Compensation
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals since July 2015. Before founding Kiniksa Pharmaceuticals in 2015, Mr. Patel founded Synageva BioPharma Corp. in June 2008 a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 8.8yrs | US$5.30m | 4.57% $ 57.1m | |
| Senior VP & CFO | 3.3yrs | no data | 0.027% $ 332.0k | |
| Senior VP & COO | 2.3yrs | US$1.75m | 0.18% $ 2.2m | |
| Chief Accounting Officer & Group VP of Finance | 4.2yrs | no data | 0.030% $ 377.3k | |
| Senior VP of Technical Operations | 3.3yrs | no data | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Compliance Officer | 3yrs | no data | no data | |
| SVP, General Counsel & Secretary | 3.3yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | no data | no data | no data | |
| Senior VP & Chief Medical Officer | 7.7yrs | US$1.79m | 0.068% $ 845.7k | |
| Executive Vice President of Corporate Affairs | no data | no data | no data | |
| Senior Vice President of Regulatory Affairs | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
52yo
Average Age
Experienced Management: KNSA's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 8.8yrs | US$5.30m | 4.57% $ 57.1m | |
| Independent Director | 6.2yrs | US$362.66k | 0.0071% $ 88.4k | |
| Lead Independent Director | 8.5yrs | US$411.06k | 0.27% $ 3.4m | |
| Independent Director | 7.3yrs | US$380.36k | 0.0071% $ 88.4k | |
| Independent Director | 8.5yrs | US$372.55k | 0.0071% $ 88.4k | |
| Independent Director | 5.1yrs | US$459.75k | 0.011% $ 137.5k | |
| Independent Director | 3.8yrs | US$365.36k | 0.0071% $ 88.4k | |
| Independent Director | 8.5yrs | US$371.96k | 0.0071% $ 88.4k | |
| Chairman of Scientific Advisory Board | no data | no data | 2.4% $ 29.9m | |
| Independent Director | 6.2yrs | US$365.36k | 0.0071% $ 88.4k |
7.3yrs
Average Tenure
55yo
Average Age
Experienced Board: KNSA's board of directors are considered experienced (7.3 years average tenure).